^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIF13A-ALK fusion

    i
    Other names: KIF13A, Kinesin Family Member 13A, RBKIN, BA500C11.2, Kinesin-Like Protein KIF13A, Kinesin-Like Protein RBKIN, Homolog Of Mouse KIF13A Mannose-6-Phosphate Receptor Transporter, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238; 63971
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    11ms
    First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient and response to alectinib with a 4-year follow-up. (PubMed, Front Genet)
    Initially undergoing chemotherapy and then crizotinib, she achieved a partial response (PR) before progressing with multiple bone metastases. This report of a KIF13A-ALK fusion case benefit significantly from alectinib with extensive follow-up. The case diversifies the array of ALK fusion partners and holds clinical relevance in refining therapeutic choices for KIF13A-ALK fusion-associated lung cancer.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • KIF13A (Kinesin Family Member 13A)
    |
    ALK fusion • KIF13A-ALK fusion
    |
    Xalkori (crizotinib) • Alecensa (alectinib)